BRPI1016167A2 - compostos heterocíclicos antivirais. - Google Patents

compostos heterocíclicos antivirais.

Info

Publication number
BRPI1016167A2
BRPI1016167A2 BRPI1016167A BRPI1016167A BRPI1016167A2 BR PI1016167 A2 BRPI1016167 A2 BR PI1016167A2 BR PI1016167 A BRPI1016167 A BR PI1016167A BR PI1016167 A BRPI1016167 A BR PI1016167A BR PI1016167 A2 BRPI1016167 A2 BR PI1016167A2
Authority
BR
Brazil
Prior art keywords
heterocyclic compounds
antiviral
antiviral heterocyclic
compounds
hepatitis
Prior art date
Application number
BRPI1016167A
Other languages
English (en)
Inventor
Kyung Lee Eun
Xavier Talamas Francisco
Craig Schoenfeld Ryan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1016167A2 publication Critical patent/BRPI1016167A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos heterociclicos antivirais compostos tendo a fórmula i abaixo: em que r', r2, r3, r4, r5a, r5b, r5c e r6 são, como definidos aqui, inibidores da polimerase ns5b do vírus da hepatite c. também são descritos composições e métodos para tratar uma infecção por hcv e inibir a replicação do hcv.
BRPI1016167A 2009-04-25 2010-04-22 compostos heterocíclicos antivirais. BRPI1016167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17272309P 2009-04-25 2009-04-25
PCT/EP2010/055309 WO2010122082A1 (en) 2009-04-25 2010-04-22 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
BRPI1016167A2 true BRPI1016167A2 (pt) 2019-07-16

Family

ID=42352760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016167A BRPI1016167A2 (pt) 2009-04-25 2010-04-22 compostos heterocíclicos antivirais.

Country Status (12)

Country Link
US (1) US8158803B2 (pt)
EP (1) EP2421831A1 (pt)
JP (1) JP2012524752A (pt)
KR (1) KR20120011880A (pt)
CN (1) CN102448936A (pt)
AU (1) AU2010240888A1 (pt)
BR (1) BRPI1016167A2 (pt)
CA (1) CA2758838A1 (pt)
IL (1) IL215713A0 (pt)
MX (1) MX2011011112A (pt)
SG (1) SG175774A1 (pt)
WO (1) WO2010122082A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110094352A (ko) * 2008-12-22 2011-08-23 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
JP5832420B2 (ja) 2009-03-25 2015-12-16 アッヴィ・インコーポレイテッド 抗ウィルス性化合物およびこの使用
CN104211644B (zh) * 2014-08-28 2016-08-24 上海毕得医药科技有限公司 一种3,4-二氯哒嗪的合成方法
EP3534888B1 (en) * 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US11026958B2 (en) 2016-11-01 2021-06-08 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CA3073212A1 (en) * 2017-09-19 2019-03-28 Merck Sharp & Dohme Corp. Heteroaryl allosteric modulators of nicotinic acetylcholine receptors
JP7060775B2 (ja) * 2018-04-10 2022-04-27 国立感染症研究所長 新規化合物
TW202120495A (zh) * 2019-08-02 2021-06-01 美商愛彼特生物製藥股份有限公司 經取代環丙基—２，２＇—聯嘧啶基化合物、其類似物及其使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1160223B1 (en) 1999-12-24 2007-03-21 Asahi Glass Company Ltd. Silicon nitride filter and method of manufacture thereof
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
AU2002359320A1 (en) 2001-10-29 2003-05-12 Smithkline Beecham Corporation Novel anit-infectives
WO2003059356A2 (en) 2001-10-30 2003-07-24 Smithkline Beecham Corporation Novel anti-infectives
AU2003248566A1 (en) 2002-05-24 2003-12-12 Smithkline Beecham Corporation Novel anti-infectives
EP2361913A1 (en) 2002-11-01 2011-08-31 Abbott Laboratories Anti-infective agents
WO2004052313A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
WO2004052312A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
WO2004058150A2 (en) 2002-12-17 2004-07-15 Smithkline Beecham Corporation Anti-infectives
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
EP1786807B1 (en) 2004-08-23 2009-07-29 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
KR20070116682A (ko) 2005-05-04 2007-12-10 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스성 화합물
MX2010002318A (es) 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
AR068107A1 (es) 2007-08-29 2009-11-04 Schering Corp Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
JP5179585B2 (ja) 2007-08-29 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 四環系インドール誘導体およびその使用法
AR070027A1 (es) 2007-09-17 2010-03-10 Abbott Lab Agentes anti-infecciosos contra el virus hcv
CN104628655A (zh) 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
EP2548873A1 (en) * 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
JP5416708B2 (ja) 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
ES2383273T3 (es) * 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
CN102164909A (zh) * 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
JP5832420B2 (ja) 2009-03-25 2015-12-16 アッヴィ・インコーポレイテッド 抗ウィルス性化合物およびこの使用
RU2552533C2 (ru) 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения

Also Published As

Publication number Publication date
CN102448936A (zh) 2012-05-09
US20100272677A1 (en) 2010-10-28
IL215713A0 (en) 2012-01-31
CA2758838A1 (en) 2010-10-28
MX2011011112A (es) 2011-11-18
JP2012524752A (ja) 2012-10-18
SG175774A1 (en) 2011-12-29
AU2010240888A1 (en) 2011-11-17
US8158803B2 (en) 2012-04-17
EP2421831A1 (en) 2012-02-29
WO2010122082A1 (en) 2010-10-28
KR20120011880A (ko) 2012-02-08

Similar Documents

Publication Publication Date Title
BR112012015951A2 (pt) 4 azido-nucleosídeos como compostos anti-hcv
BRPI1016167A2 (pt) compostos heterocíclicos antivirais.
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
DOP2010000052A (es) Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
TW200745151A (en) Antiviral nucleosides
CO6300958A2 (es) Nucleosidos de imidazol[1,5-f][1,2,4]triazinil, imidazol[1,2-f]1,2,4]triazinil y [1,2,4]triazolo[4,3-f][1,2,4]triazinil para tratamiento antiviral.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
ECSP10010210A (es) Compuestos nucleósidos antivirales
ATE483712T1 (de) Hcv-ns5b-inhibitoren
MY157435A (en) Heterocyclic antiviral compounds
BR112013020042A2 (pt) inibidores de vírus da hepatite c
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
MX2011012541A (es) Compuestos heterociclicos antivirales.
MX2012006513A (es) Compuestos heterociclicos antivirales.
BRPI0716060A2 (pt) inibidores de polimerase viral.
MX2011012240A (es) Compuestos heterociclicos antivirales.
BR112013000245A2 (pt) compostos antivirais heterocíclicos
BR112012012085A2 (pt) compostos antivirais heterocíclicos
MX2012002958A (es) Compuestos antivirales heterociclicos.
ATE531373T1 (de) Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
IL193113A0 (en) Heterocyclic antiviral compounds
MX2013001273A (es) Compuestos heterociclicos antivirales.
UA106081C2 (uk) Гетероциклічні противірусні сполуки

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]